Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 4/20 | 0.52 |
| ▸ | GABRB2 known ✓ | P47870 | 4/20 | 0.52 |
| ▸ | SCN5A known ✓ | Q14524 | 2/20 | 0.35 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.35 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.35 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.35 |
| ▸ | ATP4A | P20648 | 1/20 | 0.42 |
| ▸ | ATP4B | P51164 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL262868 | 0.97 | GABRA1 (0.55) | GABRA1GABRB2ATP4AATP4BPOLB | |
| SCHEMBL1332031 | 0.97 | GABRA1 (0.55) | GABRA1GABRB2ATP4AATP4BPOLB | |
| Propane SCHEMBL27547406 | 0.94 | GABRA1 (0.52) | GABRA1GABRB2ATP4AATP4BPOLB | |
| Methane SCHEMBL28083182 | 0.94 | GABRA1 (0.52) | GABRA1GABRB2ATP4AATP4BPOLB | |
| SCHEMBL30319989 | 0.94 | GABRA1 (0.52) | GABRA1GABRB2ATP4AATP4BPOLB | |
| SCHEMBL28144550 | 0.94 | GABRA1 (0.52) | GABRA1GABRB2ATP4AATP4BPOLB | |
| SCHEMBL28967677 | 0.94 | GABRA1 (0.52) | GABRA1GABRB2ATP4AATP4BPOLB | |
| Hydrochloric Acid SCHEMBL28782819 | 0.92 | GABRA1 (0.50) | GABRA1GABRB2ATP4AATP4BPOLB | |
| SCHEMBL30303201 | 0.90 | GABRA1 (0.48) | GABRA1GABRB2ATP4AATP4BPOLB | |
| SCHEMBL350947 | 0.90 | GABRA1 (0.54) | GABRA1GABRB2ATP4AATP4BPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105693526-A | Preparation method of 4,4'-methylene-bis-(3-chloro-2,6-diethylaniline) | 衢州信步化工科技有限公司 | 2016-06-22 | — | — | CN | claimed |
| WO-2012019759-A2 | COMPOSITIONS FOR THE PRODUCTION OF POLYURETHANES WITH ADJUSTABLE GEL TIME | LONZA LTD (CH) | 2012-02-16 | — | — | WO | claimed |
| EP-1897881-A2 | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders | Biovitrum AB (publ) (SE) | 2008-03-12 | — | — | EP | claimed |
| CN-101081845-A | Substituted sulphone and sulphonamide compounds useful for the treatment of obesity, type II diabetes and cns disorders | BIOVITRUM AB (SE) | 2007-12-05 | — | — | CN | claimed |
| CN-1662521-A | Novel compounds useful for the treatment of obesity, type II diabetes and CNS disorders | BIOVITRUM AB (SE) | 2005-08-31 | — | — | CN | claimed |
| EP-1513828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | Biovitrum AB (SE) | 2005-03-16 | — | — | EP | claimed |
| US-20040024210-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-05 | — | — | US | claimed |
| WO-2004000828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | claimed |
| EP-1964860-B1 | ETHYLENE POLYMER, CATALYST FOR PRODUCTION OF ETHYLENE POLYMER, AND PROCESS FOR PRODUCTION OF ETHYLENE POLYMER | TOSOH CORP (JP) | 2017-07-05 | — | — | EP | disclosed |
| CN-106349103-A | Method for preparing N-dichloro methylene aniline type compound | 浙江工业大学 | 2017-01-25 | — | — | CN | disclosed |
| CN-106316880-A | Synthetic method of N-dichloromethylene aniline derivative | 浙江工业大学 | 2017-01-11 | — | — | CN | disclosed |
| CN-105693526-A | Preparation method of 4,4'-methylene-bis-(3-chloro-2,6-diethylaniline) | 衢州信步化工科技有限公司 | 2016-06-22 | — | — | CN | disclosed |
| CN-105693526-A | Preparation method of 4,4'-methylene-bis-(3-chloro-2,6-diethylaniline) | 衢州信步化工科技有限公司 | 2016-06-22 | — | — | CN | disclosed |
| US-8841396-B2 | Ethylene-α-olefin copolymer and molded article | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-09-23 | — | — | US | disclosed |
| WO-2001030915-A1 | 8-(ANILINO)-1-NAPHTHALENESULFONATE ANALOGS AND THEIR USE IN ANALYTE DETECTION ASSAYS | LIFESCAN, INC. (US) | 2001-05-03 | — | — | WO | disclosed |
| US-6218571-B1 | COUPLING WITH 3-METHYL-2-BENZOTHIAZOLINONE HYDRAZONE HYDROCHLORIDE TO MAKE DYE; REDUCED DRIFT; GLUCOSE DETECTION IN BLOOD | LIFESCAN, INC. | 2001-04-17 | — | — | US | disclosed |
| US-6110858-A | AN OLEFIN POLYMERIZATION CATALYST CONSISTS OF A TRANSITION METAL COMPOUND, A MODIFIED CLAY COMPOUND CONTAINING CLAY MINERAL AND AN AMINE COMPOUND AND AN ORGANOALUMINUM COMPOUND | TOSOH CORPORATION (JP) | 2000-08-29 | — | — | US | disclosed |
| EP-0849292-A1 | Olefin polymerisation catalysts and processes for producing olefin polymers | TOSOH CORPORATION (JP) | 1998-06-24 | — | — | EP | disclosed |
| US-4289906-A | Chemical process for preparing methylene bis-anilines | ETHYL CORPORATION (US) | 1981-09-15 | — | — | US | disclosed |
| US-RE29468-E | Process for making a C1 -C7 aliphatic hydrocarbyl ester of an N-[2,6-di(C1 -C7 alkyl)phenyl] α-aminocarboxylic acid | HERCULES INCORPORATED (US) | 1977-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024210-A1 | New compounds | SULT1E1, SULT2A1, SULT1A1 | GABRA1 480/4885GABRB2 86/4885SCN5A 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.